We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals

188 hedge funds and large institutions have $1.81B invested in Agios Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 62 increasing their positions, 57 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 23

48% more capital inflows, than outflows

Capital inflows: $225M | Capital outflows: $152M

11% more funds holding

Funds holding: 170 → 188 (+18)

3.18% more ownership

Funds ownership: 107.17% → 110.36% (+3.2%)

9% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 57

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

20% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $15.5M

Holders
188
Holders Change
+18
Holders Change %
+10.59%
% of All Funds
2.7%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
41
Increased
62
Reduced
57
Closed
23
Calls
$12.5​M
Puts
$15.5​M
Net Calls
-⁠$3.02​M
Net Calls Change
-⁠$1.92​M

AGIO Hedge Fund Activity: Q1 2024 in Review

188 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2024, worth a combined $1.81B — up 36% from $1.33B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new AGIO positions and 23 closed out — a net gain of 18 holders — while 62 added to existing stakes and 57 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $38.1M. The largest seller was First Trust Advisors, exiting entirely with an estimated $40.5M sold.

  • 188 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2024, up from 170 in Q4 2023.
  • Funds reported $1.81B of Agios Pharmaceuticals stock for Q1 2024, up 36% quarter-over-quarter.
  • 41 funds opened new Agios Pharmaceuticals positions in Q1 2024 and 23 closed out, a net change of +18 holders.
  • The largest Agios Pharmaceuticals buyer in Q1 2024 was Farallon Capital Management, an estimated $38.1M added.
  • The largest Agios Pharmaceuticals seller in Q1 2024 was First Trust Advisors, an estimated $40.5M sold.

Based on aggregated 13F filings for Q1 2024.